NVIDIA Ignites the Next Frontier: Partnering with Johnson & Johnson and Eli Lilly to Revolutionize the Trillion-Dollar Pharmaceutical Industry with AI-Powered Surgery and Drug Manufacturing

According to the Zhisheng Finance APP, Nvidia (NVDA.US) CEO said on Tuesday that Johnson & Johnson (JNJ.US) and Eli Lilly and Company (LLY.US) are leveraging Nvidia's technology to optimize existing products or aid in the development of new therapies.

At NVIDIA's GTC conference held in Washington, Jensen Huang noted that Johnson & Johnson is already using NVIDIA products to train some surgical robots and simulate surgical procedures through "digital twin" technology.

He said, "These Johnson & Johnson surgical robots will even be able to perform non-invasive surgeries with a level of precision unprecedented globally."

Huang Renxun also mentioned that NVIDIA and Eli Lilly have reached a new cooperation - the two parties will jointly build a supercomputer. The computer will serve as an "artificial intelligence factory," used not only for discovering new drugs but also for improving drug production processes.

Eli Lilly's Senior Vice President and Chief AI Officer Thomas Fuchs said in a statement: "By embedding intelligence at every layer of our workflow, we are opening the door to a new type of enterprise model: one that continuously learns, adapts, and improves itself through every data point. It’s not just about speed; it’s about exploring biological principles on a large scale, deepening our understanding of diseases, and translating these insights into meaningful medical advances for humanity…"

This supercomputer will be the first Nvidia DGX SuperPOD based on the Blackwell architecture and equipped with the DGX B300 system, powered by more than 1,000 B300 graphics processing units (GPUs).